| P/E (FY) | — | Sales (TTM) | $70.9M |
| Earnings (TTM) | -$360.6M | ROE | −49.16% |
| Net Margin | −483.57% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 241.95% |
Viridian Therapeutics discovers, develops, and commercializes treatments for serious and rare diseases. It develops IGF-1R therapies for thyroid eye disease, including Veligrotrug, an intravenous monoclonal antibody, and Elegrobart, a subcutaneous candidate, plus an anti-TSHR candidate for Graves' disease and thyroid eye disease. Its FcRn inhibitor portfolio includes VRDN-006 and VRDN-008. The company was formerly known as Miragen Therapeutics.
| Market Cap | $2.01B | Trading Days | 1359 |
| 52W High | 34.29 |
| 52W Low | 13.18 |
| % Off High | −43.10% |
| YTD | −37.31% | 1Y | 13.04% |
| 3Y | 4.22% | 5Y | 16.13% |
| Since incept. (ann.) | 0.78% |
License 99% · Collaboration 1%
| Ann. Volatility (1Y) | 72.65% | Ann. Volatility (3Y) | 66.82% |
| Sharpe (1Y) | 0.55 | Sharpe (3Y) | 0.37 |
| Max Drawdown (1Y) | −60.63% | Max Drawdown (3Y) | −60.63% |
| Beta (3Y, vs SPY) | 1.85 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| RAPP | Rapport Therapeutics, Inc. | $2.01B | — |
| URGN | UroGen Pharma Ltd. | $1.99B | — |
| ZBIO | Zenas BioPharma, Inc. | $2.04B | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.98B | 24.4 |
| PVLA | PALVELLA THERAPEUTICS, INC. | $2.05B | — |
| PGEN | PRECIGEN, INC. | $1.97B | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.07B | 13.2 |
| BHVN | Biohaven Ltd. | $2.07B | — |
| IMUX | IMMUNIC, INC. | $2.08B | — |
| SION | Sionna Therapeutics, Inc. | $2.10B | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.92B | 7.2 |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $2.14B | — |
